A single institutional experience: is epoetin alpha effective in anemic children with cancer?

Area of Science:

• Pediatric Oncology
• Hematology
• Pharmacology

Background:

• Anemia is a common complication in children undergoing cancer treatment.
• Erythropoiesis-stimulating agents (ESAs) like epoetin-alpha are used to manage anemia.
• The efficacy of epoetin-alpha in pediatric cancer patients with different tumor types requires further investigation.

Purpose of the Study:

• To evaluate the effectiveness of epoetin-alpha in improving hemoglobin levels.
• To assess the impact of epoetin-alpha on red blood cell transfusion needs.
• To compare outcomes in children with hematologic malignancy versus solid tumors.

Main Methods:

• A prospective study involving pediatric patients with hematologic malignancy (n=27) and solid tumors (n=14).
• Epoetin-alpha administered at doses of 150 U/kg or 250 U/kg, thrice weekly for 12 weeks.
• Hemoglobin levels and red blood cell transfusion requirements were monitored throughout the study.

Main Results:

• Epoetin-alpha significantly increased hemoglobin levels at 2 and 3 months of therapy (p <.05).
• Patients required fewer red blood cell transfusions by the third month of treatment.
• At 150 U/kg, only 3/27 hematologic malignancy patients needed transfusions, while no solid tumor patients did. At 250 U/kg, no transfusions were needed after the second month.

Conclusions:

• Epoetin-alpha is effective in increasing hemoglobin levels in pediatric cancer patients.
• Epoetin-alpha reduces the requirement for red blood cell transfusions in this population.
• The findings support the use of epoetin-alpha for managing anemia in children with malignancy.